Abstract
Therapeutic proteins, such as infliximab, have revolutionized the treatment of many diseases during the last decade and more than 80 therapeutic proteins are currently approved for clinical use. However, all exogenous proteins have the potential to cause antibody formation. In order to ensure patient safety and the efficacy of therapeutic proteins, careful monitoring of the immunogenicity of therapeutic proteins is therefore necessary not only during preclinical trials, but also during the treatment of patients. Here, we report a clear-cut demonstration of the induction of anti-infliximab antibodies during the treatment of a patient with ankylosing spondylitis (AS). Assessment of anti-infliximab antibodies in sera obtained at various time periods were performed using a highly specific double antigen assay system developed in our laboratory. Immunoreactivity was found to be solely specific for infliximab. Because all sera obtained from the patient were found to be negative for the presence of human anti-mouse antibody (HAMA) and anti-human antibodies. The loss of effect of infliximab, as judged by observing the relapse of signs and symptoms of disease in the patient, seemed to be related with the appearance of antibodies. This study clearly demonstrates that monitoring for the induction of specific antibodies during clinical trials is an important issue for therapeutic proteins.
References
Hehlgans T, Mannel DN (2002) The TNF-TNF receptor system. Biol Chem 383:1581–1585
Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ et al (2001) Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15:533–543
Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331–367
MacEwan DJ (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14:477–492
Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296(5573):1634–1635
Mikuls TR, Weaver AL (2003) Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 5:270–277
Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH (2003) Infliximab treatment of rheumatoid arthritis and Crohn’s disease. Ann Pharmacother 37:1256–1265
Gladman DD (2003) Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 33:29–37
Gause A, Arbach O, Lamprecht P (2003) Treatment of primary systemic vasculitis with TNF alpha-antagonists. Z Rheumatol 62:228–234
Fleischmann R, Shealy D (2003) Developing a new generation of TNF-α antagonists for the treatment of rheumatoid arthritis. Mol Interv 3:310–318
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 354(9194):1932–1939
Sandborn WJ (2003) Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 5:501–505
Chew AL, Bennett A, Smith CH, Barker J, Kirkham B (2004) Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 151:492–496
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385–390
Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48:2224–2233
Braun J, Brandt J, Listing J, Zink A, Alten R, Gromnica-Ihle E et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359(9313):1187–1193
Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E et al (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 41:1280–1285
Baeten D, Kruithof E, Bosch F, Van den Bossche N, Herssens A, Mielants H et al (2003) Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62:829–834
Vidal F, Fontova R, Richart C (2003) Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 139:E238–E239
Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A et al (2003) Influence of immunogenicity on the long term efficacy of infliximab in Crohn’s disease. N Engl J Med 348:601–608
Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383–2390
Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N et al (2003) Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 125:32–39
Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N (2004) Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6:R535–R543
Frodin JE, Lefvert AK, Mellstedt H (1992) The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 21:153–165
Glennie MJ, Johnson PW (2000) Clinical trials of antibody therapy, Immunol Today 21:403–410
Vaughan TJ, Osbourn JK, Tempest PR (1998) Human antibodies by design. Nat Biotechnol 16:535–539
Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285
Biasi D, Carletto A, Caramaschi P, Bambara LM (1996) An update on the bath ankylosing spondylitis disease activity and functional ındices (BASDAI, BASFI): excellent Cronbach’s alpha scores. J Rheumatol 23:407–408
Aybay C, Imir T (2000) Development of a rapid, single-step procedure using protein G affinity chromatography to deplete fetal calf serum of its IgG and to isolate murine IgG1 monoclonal antibodies from supernatants of hybridoma cells. J Immunol Methods 233:77–81
Miele E, Markowitz JE, Mamula P, Baldassano RN (2004) Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38:502–508
Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J et al (2003) A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 18:751–759
Pendley C, Schantz A, Wagner C (2003) Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:172–179
Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U et al (2003) Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48:68–75
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563
LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB et al (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 86:4220–4224
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aybay, C., Ozel, S. & Aybay, C. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int 26, 473–480 (2006). https://doi.org/10.1007/s00296-005-0085-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-005-0085-0